SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-030373
Filing Date
2023-08-23
Accepted
2023-08-23 16:01:35
Documents
14
Period of Report
2023-08-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mrtx-20230817.htm   iXBRL 8-K 39396
2 EX-99.1 exhibit991-cfotransitionpr.htm EX-99.1 8851
6 image_0.jpg GRAPHIC 7290
  Complete submission text file 0001628280-23-030373.txt   189461

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20230817.xsd EX-101.SCH 1899
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20230817_lab.xml EX-101.LAB 24139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20230817_pre.xml EX-101.PRE 12510
8 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20230817_htm.xml XML 2687
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 231197570
SIC: 2834 Pharmaceutical Preparations